HK38497A - Infective drug delivery system - Google Patents
Infective drug delivery systemInfo
- Publication number
- HK38497A HK38497A HK38497A HK38497A HK38497A HK 38497 A HK38497 A HK 38497A HK 38497 A HK38497 A HK 38497A HK 38497 A HK38497 A HK 38497A HK 38497 A HK38497 A HK 38497A
- Authority
- HK
- Hong Kong
- Prior art keywords
- drug delivery
- delivery system
- infective drug
- retrovirus
- serve
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
- C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85586586A | 1986-04-24 | 1986-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK38497A true HK38497A (en) | 1997-04-04 |
Family
ID=25322287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK38497A HK38497A (en) | 1986-04-24 | 1997-03-27 | Infective drug delivery system |
Country Status (9)
Country | Link |
---|---|
US (2) | US5652130A (de) |
EP (1) | EP0243204B1 (de) |
JP (2) | JP2773833B2 (de) |
AT (1) | ATE133449T1 (de) |
CA (1) | CA1310924C (de) |
DE (1) | DE3751682T2 (de) |
ES (1) | ES2083353T3 (de) |
GR (1) | GR3019460T3 (de) |
HK (1) | HK38497A (de) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5662896A (en) * | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
DE3990262T1 (de) * | 1988-03-21 | 1991-04-04 | Viagene Inc | Rekombinante retroviren |
US6241982B1 (en) | 1988-03-21 | 2001-06-05 | Chiron Corporation | Method for treating brain cancer with a conditionally lethal gene |
US6569679B1 (en) | 1988-03-21 | 2003-05-27 | Chiron Corporation | Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene |
WO1989009271A1 (en) * | 1988-03-21 | 1989-10-05 | Viagene, Inc. | Recombinant retroviruses |
US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US6133029A (en) | 1988-03-21 | 2000-10-17 | Chiron Corporation | Replication defective viral vectors for infecting human cells |
DE69032841T2 (de) * | 1989-01-23 | 1999-05-12 | Chiron Corp | Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung |
EP0454781B1 (de) * | 1989-01-23 | 1998-12-16 | Chiron Corporation | Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung |
WO1990012087A1 (en) * | 1989-04-05 | 1990-10-18 | Novacell Corporation | Infectious targetted replication-defective virion |
US6337209B1 (en) | 1992-02-26 | 2002-01-08 | Glaxo Wellcome Inc. | Molecular constructs containing a carcinoembryonic antigen regulatory sequence |
GB8919607D0 (en) * | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
US5225347A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
ATE199398T1 (de) * | 1989-10-24 | 2001-03-15 | Chiron Corp | Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein |
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US6316003B1 (en) | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
DK0506884T3 (da) * | 1989-12-21 | 1996-11-04 | Whitehead Biomedical Inst | Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler |
US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
WO1991019803A1 (en) * | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
US5817491A (en) * | 1990-09-21 | 1998-10-06 | The Regents Of The University Of California | VSV G pseusdotyped retroviral vectors |
US5512421A (en) * | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
EP0572401B2 (de) * | 1991-02-19 | 2007-11-07 | The Regents of the University of California | Viruspartikel mit veraendertem wirtspektrum |
EP0615453B1 (de) * | 1991-11-29 | 1997-05-14 | Chiron Viagene, Inc. | Immuntherapeutische vektorkonstrukte gegen krebs |
US6297048B1 (en) | 1992-02-04 | 2001-10-02 | Chiron Corporation | Hepatitis therapeutics |
CA2158936C (en) | 1993-11-18 | 2012-02-21 | Jack R. Barber | Compositions and methods for utilizing conditionally lethal genes |
US5591625A (en) * | 1993-11-24 | 1997-01-07 | Case Western Reserve University | Transduced mesenchymal stem cells |
US5888814A (en) * | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
ES2264136T3 (es) * | 1995-02-21 | 2006-12-16 | Cantab Pharmaceuticals Research Limited | Preparaciones virales, vectores, inmunogenos y sus vacunas. |
CA2222559A1 (en) * | 1995-06-27 | 1997-01-16 | Bavarian Nordic Research Institute A/S | Encapsulated cells producing viral particles |
AU7567298A (en) * | 1997-05-09 | 1998-11-27 | Fred Hutchinson Cancer Research Center | (mus dunni) endogenous retroviral packaging cell lines |
AU7486898A (en) | 1997-05-13 | 1998-12-08 | Stuart D Edwards | Global medical treatment method and apparatus |
US5973119A (en) * | 1998-06-05 | 1999-10-26 | Amgen Inc. | Cyclin E genes and proteins |
ES2151403B1 (es) * | 1998-07-13 | 2001-07-01 | Hernandez Bronchud Miguel | Linea celular transformada de rata productora de tnf-alfa humano recombinante. |
US6344541B1 (en) * | 1998-09-25 | 2002-02-05 | Amgen Inc. | DKR polypeptides |
WO2000058479A1 (en) | 1999-03-26 | 2000-10-05 | Amgen Inc. | Beta secretase genes and polypeptides |
AU5003200A (en) | 1999-05-14 | 2000-12-05 | United States Of America As Represented By The Department Of Veterans Affairs, The | Isolation and characterization of epidermal growth factor related protein |
US7049410B2 (en) * | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
US7408047B1 (en) * | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US7459540B1 (en) * | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US6900043B1 (en) | 1999-09-21 | 2005-05-31 | Amgen Inc. | Phosphatases which activate map kinase pathways |
KR100630880B1 (ko) * | 1999-12-31 | 2006-10-02 | 엘지.필립스 엘시디 주식회사 | 엑스레이 영상 감지소자 및 그 제조방법 |
US20050239061A1 (en) * | 2000-03-01 | 2005-10-27 | Marshall William S | Identification and use of effectors and allosteric molecules for the alteration of gene expression |
US7514239B2 (en) | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
MXPA02012747A (es) | 2000-06-28 | 2003-09-25 | Amgen Inc | Moleculas del receptor de linfopoietina estromica timica y sus usos. |
CN1738649A (zh) * | 2001-07-09 | 2006-02-22 | 抗癌公司 | 用荧光蛋白作为标记物使感染成像 |
US7662924B2 (en) * | 2002-02-22 | 2010-02-16 | The Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
AU2003217693A1 (en) * | 2002-02-22 | 2003-09-09 | Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
JP4852539B2 (ja) | 2004-06-22 | 2012-01-11 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 腫瘍細胞増殖をFOXM1siRNAによって阻害する方法 |
JP2008529530A (ja) * | 2005-02-10 | 2008-08-07 | エモリー・ユニバーシティ | 向上した機能を有する新規な蛋白質及び円順列変異を使用した新規な蛋白質を生成する方法 |
US8282918B2 (en) * | 2007-07-30 | 2012-10-09 | University Of Iowa Research Foundation | Polynucleotides encoding RPA4/RPA32 hybrid polypeptides |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
UA105016C2 (uk) | 2008-10-10 | 2014-04-10 | Амген Інк. | Fgf21 мутанти і їх застосування |
EP2427207B1 (de) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21-mutanten und ihre verwendungen |
KR101860572B1 (ko) | 2009-05-05 | 2018-05-24 | 암젠 인크 | Fgf21 돌연변이체 및 이의 용도 |
CA2764835A1 (en) * | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
EP2506861A1 (de) * | 2009-12-02 | 2012-10-10 | Amgen Inc. | Bindeproteine zur bindung von humanem fgfr1c, humanem b-klotho sowie humanem fgfr1c als auch humanem b-klotho |
UA109888C2 (uk) * | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトFGF受容体およびβ−KLOTHO結合性タンパク質 |
JP6033218B2 (ja) | 2010-05-21 | 2016-11-30 | ペプティメド, インコーポレイテッド | がんを治療するための試薬および方法 |
WO2012095548A2 (es) | 2011-01-13 | 2012-07-19 | Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) | Compuestos para el tratamiento de enfermedades neurodegenerativas |
US10183058B2 (en) | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
US10172910B2 (en) | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS605692Y2 (ja) * | 1977-06-02 | 1985-02-22 | 日本電気株式会社 | 宅内機器構造 |
JPS61922Y2 (de) * | 1979-12-17 | 1986-01-13 | ||
US4405712A (en) * | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
US4769330A (en) * | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4650764A (en) * | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
GB8324800D0 (en) * | 1983-09-15 | 1983-10-19 | Pasteur Institut | Antigens |
FR2559159B1 (fr) * | 1984-02-02 | 1986-09-12 | Inst Nat Sante Rech Med | Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues |
US4663281A (en) * | 1984-03-22 | 1987-05-05 | Mass Institute Of Technology | Enhanced production of proteinaceous materials in eucaryotic cells |
US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
WO1985005629A1 (en) * | 1984-05-25 | 1985-12-19 | Dana-Farber Cancer Institute | Ltr vectors, methods of preparation and use |
WO1985005618A1 (en) * | 1984-06-06 | 1985-12-19 | Takeda Chemical Industries, Ltd. | Process for preparing interferon derivative |
WO1986000922A1 (en) * | 1984-07-30 | 1986-02-13 | The Salk Institute For Biological Studies | Retroviral gene transfer vectors |
GB8424757D0 (en) * | 1984-10-01 | 1984-11-07 | Pasteur Institut | Retroviral vector |
US4677063A (en) * | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
FR2571737B1 (fr) * | 1984-10-15 | 1987-02-20 | Agronomique Inst Nat Rech | Vecteurs de clonage ou d'expression comportant le genome du virus de l'erythroblastose aviaire et cellules transfectees par ces vecteurs |
US4725669A (en) * | 1984-11-09 | 1988-02-16 | President And Fellows Of Harvard College | Assay for detecting infection by human T-cell lymphotropic virus-III |
US4839284A (en) * | 1985-05-16 | 1989-06-13 | New York University | Murine host-vector system capable of amplifying and expressing transfected genes |
ATE68013T1 (de) * | 1985-07-05 | 1991-10-15 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5091309A (en) * | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
AU3069189A (en) * | 1988-02-05 | 1989-08-25 | Trustees Of Columbia University In The City Of New York, The | Retroviral packaging cell lines and processes of using same |
-
1987
- 1987-04-21 CA CA000535154A patent/CA1310924C/en not_active Expired - Lifetime
- 1987-04-24 DE DE3751682T patent/DE3751682T2/de not_active Expired - Fee Related
- 1987-04-24 ES ES87303651T patent/ES2083353T3/es not_active Expired - Lifetime
- 1987-04-24 JP JP62102979A patent/JP2773833B2/ja not_active Expired - Fee Related
- 1987-04-24 EP EP87303651A patent/EP0243204B1/de not_active Expired - Lifetime
- 1987-04-24 AT AT87303651T patent/ATE133449T1/de not_active IP Right Cessation
-
1994
- 1994-11-29 US US08/346,361 patent/US5652130A/en not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/467,553 patent/US5635399A/en not_active Expired - Lifetime
-
1996
- 1996-03-29 GR GR960400835T patent/GR3019460T3/el unknown
-
1997
- 1997-03-27 HK HK38497A patent/HK38497A/xx not_active IP Right Cessation
-
1998
- 1998-02-10 JP JP10028426A patent/JP2843318B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2083353T3 (es) | 1996-04-16 |
JPH10287590A (ja) | 1998-10-27 |
US5652130A (en) | 1997-07-29 |
DE3751682T2 (de) | 1996-09-12 |
CA1310924C (en) | 1992-12-01 |
DE3751682D1 (de) | 1996-03-07 |
JP2773833B2 (ja) | 1998-07-09 |
ATE133449T1 (de) | 1996-02-15 |
JPS63157985A (ja) | 1988-06-30 |
EP0243204A2 (de) | 1987-10-28 |
EP0243204A3 (en) | 1989-02-22 |
EP0243204B1 (de) | 1996-01-24 |
GR3019460T3 (en) | 1996-06-30 |
US5635399A (en) | 1997-06-03 |
JP2843318B2 (ja) | 1999-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0243204A3 (en) | Infective drug delivery system | |
IT1232243B (it) | Composizioni farmaceutiche a base di ciclosporine | |
DE3586206D1 (de) | Metoprololsuccinat und dieses enthaltende pharmazeutische zusammensetzung. | |
IL74666A0 (en) | Storage-stable,quick-disintegrating pressed shapes containing pharmaceutical active substances | |
IL90058A0 (en) | Hiv envelope peptide,vaccines containing it,monoclonal antibodies directed against said peptide and pharmaceutical compositions containing said antibodies | |
FI891774A0 (fi) | Menetelmä lääkeaineen anto- ja/tai annostelumuodon valmistamiseksi | |
IL85885A0 (en) | Cyclic peptides,their preparation and pharmaceutical compositions containing them | |
TW290455B (de) | ||
WO1993018055A3 (en) | Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160 | |
AU1226288A (en) | Processes for the preparation of medicinal compositions, compositions obtained by these processes and use thereof for the preparation of medicines against viral hepatitis b and acquired immunodeficiency syndrome | |
EP0230264A3 (en) | Pharmaceutical composition for nasal application, process for its preparation and its use | |
DE3874610D1 (de) | ||
NO180636C (no) | Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1 | |
DK439288A (da) | Laegemiddelbeholder | |
IL89118A0 (en) | Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1 | |
DE3067790D1 (en) | Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them | |
IL81949A (en) | 2-azolylmethyl-2-aryl-1,3-dioxolanes and the salts thereof,processes for their preparation and pharmaceutical compositions containing them | |
IL85651A0 (en) | Optically active oxo-isoindolinyl derivatives,their preparation and pharmaceutical compositions containing them | |
IL92441A0 (en) | Imidazole containing peptides,their preparation and pharmaceutical compositions containing them | |
EP0175323A3 (en) | Biologically active peptides, processes for preparing them and pharmaceutical compositions | |
AU4576789A (en) | Synthetic peptide derivatives of gp41 glycoprotein of HIV | |
EP0264017A3 (en) | Pharmaceutical compositions having healing activity | |
ATE64535T1 (de) | Xylometazolinhaltige pharmazeutische praeparate. | |
IL81926A0 (en) | Pharmaceutical compositions for the oral administration of active proteins | |
ATE78684T1 (de) | Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20050424 |